Compare Vanguard Mega Cap Growth ETF (MGK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.43 (market cap $33.70B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 16.7× GeneDx Holdings Corp's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and GeneDx Holdings Corp for 19 Days on average.
| MGK | WGS | |
|---|---|---|
Market Cap | $33.70B | $2.02B |
Volume | 1,362,010 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $167.51 |
52-Week Low | $70.70 | $34.51 |
Typical Hold Time | 45 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.
MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
